US Neurology Editorial Board member, David Hafler (Yale School of Medicine, Connecticut, USA) talks to us about his exciting latest research looking at regulatory T cell RNA sequencing in multiple sclerosis (MS), as well as other potential therapeutic targets.
Questions
1. What are the major gaps in our understanding of the processes underlying multiple sclerosis (MS)? (0:04)
2. How has the identification of genetic variants enhanced our understanding of MS? (1:30)
3. Could you tell us a little about your research using single-cell RNA sequencing in MS? (3:30)
4. How do environmental factors such as salt and fat contribute to regulatory T cell dysfunction in MS? (6:12)
5. What is the potential of the NF-kappaB pathway and other transcription factors as therapeutic targets in MS? (7:25)
Speaker disclosures: David Hafler has received funding from Bristol-Myers Squibb, Novartis and Genentech; he has been a consultant for Compass Therapeutics, EMD Serono, Novartis Pharmaceuticals, Sanofi Genzyme, Versant Venture, Genentech and Proclara Bioscience.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
